Top officials in the Trump administration on Tuesday announced they will limit the approval of new COVID-19 vaccines to adults over 65 and people who are high risk.

The move is a significant shift away from the current universal recommendation, and comes just two days before the Food and Drug Administration's (FDA) independent advisers are set to vote on the formula that vaccine makers should use to potentially adjust their shots for the current strain.

In a commentary published in the New England Journal of Medicine, FDA leaders wrote they will require companies to conduct lengthy clinical trials to compare the vaccine against a placebo before approving shots for healthier people.

The shots will continue to be streamlined for people over the........

© The Hill